SKIP NAVIGATION
HOME. ABOUT US.
INVESTMENT BANKING.
SYNDICATE.
INSTITUTIONAL SALES & TRADING. RESEARCH. INDIVIDUAL INVESTORS.
WEALTH MANAGEMENT.
INSURANCE. NEWS.
CONTACT.
ANALYST TEAM. REPORTS.
ANALYST TEAM
Stephen M. Dunn - Director of Research
Mr. Dunn serves as Director of Research for Dawson James Securities where he performs institutional research for both public and private companies in the biotechnology, pharmaceutical and medical device sectors.
Previous to Dawson James, he served as Director of Research for Cabot Adams LLC and held management positions in business development, finance and operations having worked in over 25 countries in North America, Europe and the Far East with Fortune 500 biomedical companies including Beckman Coulter, Cordis (Johnson & Johnson), St. Jude Medical and Telectronics.
Having over 20 years within the global biomedical industry, Mr. Dunn has negotiated numerous intellectual property licenses, product development agreements, venture funding, M&A and joint ventures with companies such as GlaxoSmithKline, Pharmacia, Novartis, Bayer, Schering AG, Wyeth, Eli Lilly, Pfizer, Genzyme, Martek Biosciences, Fisher Life Sciences, Becton Dickinson, Idec Pharmaceuticals, Ortho Diagnostics, DakoCytomation, Los Alamos and Sandia National Laboratories, the Mayo Clinic Foundation and the Dana-Farber Institute along with dozens of smaller public and private companies throughout the world.
Mr. Dunn is a registered investment advisor, a member of the Licensing Executives Society, BioFlorida, the Association for Investment Management & Research, the American Institute of CPAs and serves as the biotechnology mentor for the Economic Development Corporation as well as a board member for several companies. He is an accomplished speaker on both financial and scientific topics and has been published in several national investment publications.
John Putnam - Senior Analyst
Mr. John Putnam is a Senior Analyst at Dawson James Securities following the medical device industry. Prior to joining Dawson James in September of 2006, Mr. Putnam was a Senior Vice President at Stanford Group Company. He joined Stanford Group Company in May 2004 as a senior healthcare analyst after having been a principle and founder of Belmont Harbor Capital, a boutique investment research and merchant bank in Chicago, Illinois, established in early 2002. Mr. Putnam covers the
medical devices and technology industry as he has done for more than 30 years.
During his tenure as a medical device analyst, he has served in a similar capacity at such firms as Smith Barney, Wellington Management, L.F. Rothschild, Alex Brown & Sons, Adams, Harkness & Hill, and Gruntal. As an analyst for the past three decades, Mr. Putnam has been responsible for the technology, fundamental, regulatory and reimbursement research of the medical device industry. He spent several years in Washington D.C., focusing on regulatory and reimbursement issues impacting the medical device industry.
Mr. Putnam has extensive knowledge of many segments of the medical device and technology industry including cardiovascular, orthopedics, diagnostics, and urology. He was the first analysts on Wall Street to identify
women’s health as an investment opportunity. Mr. Putnam has a strong financial background and actually enjoys reading and analyzing financial statements and performing due diligence. Prior to changes in the institutional investment banking business which are now in place, he was intensely involved in investment banking assignments, having participated in more than 20 such transactions.
In addition to strong writing and personal communications skills, Mr. Putnam has also developed a proprietary research methodology that evaluates the competitive position of companies participating in a particular industry segment by analyzing their intellectual property as embodied in a company’s patent portfolio. This methodology can be used to perform strategic planning and business development. It identifies each company’s relative competitive position within a technology and can identify those companies that are either active or have become inactive in research and development in that specific technology. From a business development perspective it can also identify a patent portfolio that may no longer be relevant to its holder but that may be an opportunity for another company.
Mr. Putnam holds an MBA from The George Washington University and a BA from Baldwin-Wallace College. He is a Chartered Financial Analyst and a member of the Boston Security Analysts Society. Mr. Putnam has been involved in raising funds for several charitable organizations including Deborah’s Place, a women’s shelter in Chicago, the Farm Workers of Palm Beach County, and Old School Square and the Public Library in Delray Beach, Florida.
Please visit our main
site